Oxolamine

Oxolamine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R05DB07 (WHO) ;
Identifiers
	IUPAC name N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine;
CAS Number	959-14-8 ;
PubChem CID	13738;
DrugBank	DB13216 ;
ChemSpider	13143 ;
UNII	90BEA145GY;
KEGG	D07387 ;
ChEMBL	ChEMBL1620875 ;
CompTox Dashboard (EPA)	DTXSID5023403 ;
ECHA InfoCard	100.012.267
Chemical and physical data
Formula	C14H19N3O
Molar mass	245.326 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c(onc1c2ccccc2)CCN(CC)CC;
	InChI InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3 ; Key:IDCHQQSVJAAUQQ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Oxolamine is a cough suppressant that is available as a generic drug in many jurisdictions.

Oxolamine also has anti-inflammatory activity, which causes a reduction in irritation of the nerve receptors of the respiratory tract.

It is mainly used for the treatment of pharyngitis, tracheitis, bronchitis, bronchiectasis and pertussis.

Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant. It is listed as a prescription drug in New Zealand legislation. Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflammation.